Skip to main content

Table 1 Eligibility of study participants

From: The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants: protocol for a randomised controlled trial

Inclusion criteria

Exclusion criteria

1. Age 18–80 yr

2. White race

3. Physically inactive (defined as not meeting the current guidelines of 2.5 h of physical activity per wk)

4. Waist-to-height ratio ≥ 1:2 and/or waist circumference ≥ 88/102 cm (for women/men)

5. Permitted medicine should be taken at a stable dose during at least 4 wk prior to randomization and preferably remaining stable during the study.

1. Diabetes (HbA1c ≥ 48 mmol/mol or fasting glucose ≥ 7.0 mmol/L)

2. Pregnancy

3. Ischaemic heart disease

4. Atrial fibrillation

5. Treatment with:

 a. NSAIDs on a daily basis

 b. Biologic rheumatic drugs

 c. Systemic prednisolone

 d. Other immunotherapy

6. Health conditions that prevent individuals from participating in the exercise training intervention

7. Subjects who cannot undergo MRI scans (e.g., owing to kidney disease, metallic implants or claustrophobia)

  1. Abbreviations: HbA1c Glycated haemoglobin, NSAIDs Non-steroidal anti-inflammatory drugs, MRI Magnetic resonance imaging